In an unprecedented medical triumph, a team of U.S. physicians successfully used a custom gene-editing therapy to treat an infant born with the ultra-rare metabolic condition Carbamoyl phosphate synthetase 1 deficiency (CPS1), sparing what is usually a fatal outcome and offering hope for other patients with similar genetic disorders.
